US Versus European Opinions on Upfront Therapy in Hodgkin Lymphoma

July 20, 2018 – United States’ versus European perspectives on the inclusion or exclusion of bleomycin in chemotherapy combinations for advanced Hodgkin lymphoma (HL), along with the value of interim positron emission tomography (PET), were discussed in a dual presentation at the 2018 Pan Pacific Lymphoma Conference (PPLC). Ranjana Advani, MD, of Stanford University School of Medicine, and Andreas Engert, MD, of the University Hospital of Cologne … (leggi tutto)